PL3475699T3 - Ulepszone oznaczenia farmakokinetyczne dla pojedynczych domen zmiennych immunoglobuliny - Google Patents
Ulepszone oznaczenia farmakokinetyczne dla pojedynczych domen zmiennych immunoglobulinyInfo
- Publication number
- PL3475699T3 PL3475699T3 PL17737492.3T PL17737492T PL3475699T3 PL 3475699 T3 PL3475699 T3 PL 3475699T3 PL 17737492 T PL17737492 T PL 17737492T PL 3475699 T3 PL3475699 T3 PL 3475699T3
- Authority
- PL
- Poland
- Prior art keywords
- variable domains
- single variable
- immunoglobulin single
- improved pharmacokinetic
- pharmacokinetic assays
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/549—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic with antigen or antibody entrapped within the carrier
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662353784P | 2016-06-23 | 2016-06-23 | |
| PCT/EP2017/065219 WO2017220645A1 (en) | 2016-06-23 | 2017-06-21 | Improved pharmacokinetic assays for immunoglobulin single variable domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3475699T3 true PL3475699T3 (pl) | 2022-09-26 |
Family
ID=59313197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17737492.3T PL3475699T3 (pl) | 2016-06-23 | 2017-06-21 | Ulepszone oznaczenia farmakokinetyczne dla pojedynczych domen zmiennych immunoglobuliny |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190195866A1 (pl) |
| EP (2) | EP3475699B1 (pl) |
| JP (1) | JP7150618B2 (pl) |
| KR (1) | KR102374912B1 (pl) |
| CN (1) | CN109313183B (pl) |
| AU (1) | AU2017281421B2 (pl) |
| BR (1) | BR112018076569A2 (pl) |
| CA (1) | CA3029133C (pl) |
| ES (1) | ES2926014T3 (pl) |
| IL (1) | IL263704B2 (pl) |
| MX (1) | MX2018016413A (pl) |
| PL (1) | PL3475699T3 (pl) |
| PT (1) | PT3475699T (pl) |
| RU (1) | RU2765809C2 (pl) |
| SG (1) | SG11201811280QA (pl) |
| WO (1) | WO2017220645A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019099999A1 (en) * | 2017-11-20 | 2019-05-23 | Vector Laboratories, Inc. | Methods and systems for species-on-species immunoassay detection |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| WO2004041862A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| RU2357974C2 (ru) | 2003-01-10 | 2009-06-10 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| WO2006059108A2 (en) | 2004-12-02 | 2006-06-08 | Domantis Limited | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES |
| RU2464276C2 (ru) | 2005-05-18 | 2012-10-20 | Аблинкс Н.В. | Улучшенные нанотела против фактора некроза опухоли-альфа |
| DK2444424T3 (en) | 2005-05-20 | 2018-12-03 | Ablynx Nv | IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS |
| CN102875681A (zh) * | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| CN101454344A (zh) | 2005-12-01 | 2009-06-10 | 杜门蒂斯有限公司 | 与白细胞介素-1受体1型结合的非竞争性域抗体形式 |
| CA2629850A1 (en) | 2005-12-01 | 2007-06-07 | Domantis Limited | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| AU2007209201A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
| EP2010568A1 (en) * | 2006-04-14 | 2009-01-07 | Ablynx N.V. | Dp-78-like nanobodies |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| WO2012130874A1 (en) * | 2011-03-28 | 2012-10-04 | Ablynx Nv | Bispecific anti-cxcr7 immunoglobulin single variable domains |
| JP2010527005A (ja) * | 2007-05-07 | 2010-08-05 | ワイス・エルエルシー | 抗炭水化物抗体によって生じるイムノアッセイにおける妨害の除去 |
| CN101970490A (zh) | 2007-11-27 | 2011-02-09 | 埃博灵克斯股份有限公司 | 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽 |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| AU2009248049B2 (en) | 2008-05-16 | 2015-07-23 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| EP2438087B1 (en) | 2009-06-05 | 2017-05-10 | Ablynx N.V. | Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections |
| RS67588B1 (sr) * | 2009-12-14 | 2026-01-30 | Ablynx Nv | Antitela sa pojedinačnim varijabilnim domenom imunoglobulina protiv ox40l, konstrukti i njihova terapijska upotreba |
| WO2012042026A1 (en) * | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
| PH12022550313A1 (en) * | 2011-06-23 | 2023-01-23 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP3466972B1 (en) | 2011-06-23 | 2026-03-04 | Ablynx NV | Serum albumin binding proteins |
| AU2012273928A1 (en) * | 2011-06-23 | 2014-02-06 | Ablynx Nv | Immunoglobulin single variable domains directed against IgE |
| FR2979099B1 (fr) | 2011-08-16 | 2014-02-28 | Oreal | Tete de distribution de produit pour un recipient et dispositif de distribution associe |
| PH12014500380A1 (en) * | 2011-08-17 | 2022-05-02 | Glaxo Group Ltd | Modified proteins and peptides |
| CN103293299B (zh) * | 2012-02-24 | 2016-06-08 | 珀金埃尔默医学诊断产品（上海）有限公司 | 拓宽双抗体夹心免疫检测浓度范围的方法及其试剂盒 |
| CN103884842A (zh) * | 2014-04-03 | 2014-06-25 | 王少雄 | 针对elisa检测用特异性抗体对的筛选方法 |
| HUE050007T2 (hu) | 2014-05-16 | 2020-11-30 | Ablynx Nv | Immunglobulin variábilis domének |
| DK3143403T3 (da) * | 2014-05-16 | 2022-01-17 | Ablynx Nv | Fremgangsmåder til påvisning og/eller måling af anti-lægemiddelantistoffer, især behandlingsinducerede anti-lægemiddelantistoffer |
| CN104597232B (zh) * | 2014-12-03 | 2017-05-03 | 中国科学院理化技术研究所 | 一种可扩展检测范围的捕获抗体竞争夹心免疫检测方法及生物传感器 |
-
2017
- 2017-06-21 CN CN201780038584.3A patent/CN109313183B/zh active Active
- 2017-06-21 PT PT177374923T patent/PT3475699T/pt unknown
- 2017-06-21 WO PCT/EP2017/065219 patent/WO2017220645A1/en not_active Ceased
- 2017-06-21 JP JP2018567281A patent/JP7150618B2/ja active Active
- 2017-06-21 CA CA3029133A patent/CA3029133C/en active Active
- 2017-06-21 BR BR112018076569A patent/BR112018076569A2/pt active Search and Examination
- 2017-06-21 EP EP17737492.3A patent/EP3475699B1/en active Active
- 2017-06-21 SG SG11201811280QA patent/SG11201811280QA/en unknown
- 2017-06-21 EP EP22178896.1A patent/EP4119944A1/en not_active Withdrawn
- 2017-06-21 MX MX2018016413A patent/MX2018016413A/es unknown
- 2017-06-21 KR KR1020197002311A patent/KR102374912B1/ko active Active
- 2017-06-21 RU RU2019101609A patent/RU2765809C2/ru active
- 2017-06-21 US US16/310,291 patent/US20190195866A1/en active Pending
- 2017-06-21 PL PL17737492.3T patent/PL3475699T3/pl unknown
- 2017-06-21 IL IL263704A patent/IL263704B2/en unknown
- 2017-06-21 ES ES17737492T patent/ES2926014T3/es active Active
- 2017-06-21 AU AU2017281421A patent/AU2017281421B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019101609A (ru) | 2020-07-23 |
| EP3475699B1 (en) | 2022-07-06 |
| EP3475699A1 (en) | 2019-05-01 |
| IL263704B2 (en) | 2024-09-01 |
| SG11201811280QA (en) | 2019-01-30 |
| PT3475699T (pt) | 2022-08-30 |
| ES2926014T3 (es) | 2022-10-21 |
| BR112018076569A2 (pt) | 2019-04-02 |
| US20190195866A1 (en) | 2019-06-27 |
| RU2765809C2 (ru) | 2022-02-03 |
| JP2019522796A (ja) | 2019-08-15 |
| CN109313183B (zh) | 2022-10-21 |
| CN109313183A (zh) | 2019-02-05 |
| AU2017281421A1 (en) | 2019-01-24 |
| MX2018016413A (es) | 2019-05-09 |
| AU2017281421B2 (en) | 2024-07-25 |
| KR102374912B1 (ko) | 2022-03-16 |
| KR20190020806A (ko) | 2019-03-04 |
| EP4119944A1 (en) | 2023-01-18 |
| IL263704A (en) | 2019-01-31 |
| CA3029133A1 (en) | 2017-12-28 |
| WO2017220645A1 (en) | 2017-12-28 |
| IL263704B1 (en) | 2024-05-01 |
| CA3029133C (en) | 2024-04-30 |
| RU2019101609A3 (pl) | 2020-07-23 |
| JP7150618B2 (ja) | 2022-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281755A (en) | Enhanced variable complexes of immunoglobulins | |
| IL325246A (en) | Anti-BCMA antibodies containing only heavy chains | |
| PT3374392T (pt) | Domínios variáveis de imunoglobulina que se ligam a albumina sérica melhorados | |
| IL257359B (en) | Humanized antibodies against the ccr7 receptor | |
| SG10201603721TA (en) | Anti-CTLA-4 Antibodies | |
| GB201601073D0 (en) | Antibodies | |
| GB201601077D0 (en) | Antibody molecule | |
| ZA201807167B (en) | Humanized anti-il-1r3 antibodies | |
| GB201610044D0 (en) | Antibodies | |
| GB201616699D0 (en) | Antibodies | |
| GB201603291D0 (en) | Antibodies | |
| GB201612337D0 (en) | Ant-il-22r antibodies | |
| SG11201705623VA (en) | Immunoglobulin assays using nanoparticles | |
| IL263704A (en) | Improved pharmacokinetic testing for single immunoglobulin variable sites | |
| GB201511196D0 (en) | Monoclonal antibodies | |
| GB201620414D0 (en) | Antibodies | |
| GB201615224D0 (en) | Antibodies | |
| GB201613158D0 (en) | Antibodies | |
| GB201612437D0 (en) | Anti-lag-3 antibodies |